TR
Third Rock Ventures
Venture CapitalActiveThird Rock Ventures invests in transformational life science companies that show high growth potential
105
Investments
10
Exits
$5.5B
AUM
9.5%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Third Rock Ventures.
Investment Thesis & Strategy
Third Rock Ventures invests in life science and healthcare companies across various stages, seeking high-growth potential and transformational impact.
Notable Exits
CompanyTypeYearValue / Acquirer
Goldfinch BioAcquisition2024—
EpizymeAcquisition2022$1.4B
GRAILAcquisition2021$8B
MyoKardiaAcquisition2020$13.1B
Blueprint MedicinesIPO2019$4.5B
Foundation MedicineAcquisition2018$5.3B
Voyager TherapeuticsIPO2017$600M
Sage TherapeuticsIPO2017$9.3B
Agios PharmaceuticalsIPO2013$1.4B
Alnylam PharmaceuticalsIPO2004$1.8B
Frequently Asked Questions
Third Rock Ventures focuses on Series A, Series B, Series C+ stage investments.